Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

325.62 +12.90 (+4.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
Here's How You Can Earn $10,000 a Year in Retirement
Getting rich is as simple as buying and holding for the long haul. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Eli Lilly's Mirikizumab Improves Fatigue in Crohn's Disease Patients
As a part of a pre-specified analysis of the Phase 2 SERENITY study, new data showed that Eli Lilly And Co's (NYSE: LLY) mirikizumab improved fatigue in... 
Via Benzinga
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.... 
Via Benzinga
Exposures Product Safety
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients
Eli Lilly and Co (NYSE: LLY) has reported topline data from Phase 3 SURPASS-4 clinical trial evaluating tirzepatide in adults with type 2 diabetes and increased... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Why Novo Nordisk Is Still a Top Stock for 2021
This stock could be a great addition to any long-term portfolio. 
Via The Motley Fool
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA
The FDA has accepted to review Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly and Co's (NYSE: LLY) marketing application for sintilimab injection... 
Via Benzinga
Exposures Product Safety
Friday Of The Heavy Week
There is nothing like a pending weekend to push Wall Street into recuperation and this worked today 
Via Talk Markets
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug
AbCellera stock crumbled Friday after the company guided to lower royalties from Covid treatment partner Eli Lilly in the second quarter. 
Via Investor's Business Daily
Value Stocks 2021 - Eli Lilly And Co.
Eli Lilly’s main source of income comes from the United States, where it generates more than 57% of its revenue. The rest is coming from Europe Rest of the world, and Japan. 
Via Talk Markets
Lilly, MiNA Ink Broad RNA Deal Worth $1.25B
Eli Lilly and Company (NYSE: LLY) has struck a deal with MiNA Therapeutics to develop small activating RNA (saRNA) candidates against up to five... 
Via Benzinga
Biden's Budget May Boost These 3 Biotechs
It signals a big push toward curing a neurological disease with a massive market. 
Via The Motley Fool
Exposures COVID-19
Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial... 
Via Benzinga
These Top 2 Healthcare Companies Are in a Race to Riches
Which diabetes drug maker will win this photo finish for investors? 
Via The Motley Fool
Eli Lilly Under FDA Scrutiny At Its COVID-19 Drug Manufacturing Facilities Amid Staff Accusations: Reuters
Eli Lilly & Co (NYSE: LLY) employees have reportedly accused a factory executive of altering documents required by the FDA to downplay quality control... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Eli Lilly Is Still a Top Stock for 2021
You might want to consider adding this pharmaceutical giant to your portfolio. 
Via The Motley Fool
Market Briefing For Wednesday, May 5
Janet Yellen said 'interest rates may need to rise moderately', and that's a part of the backdrop, though S&P has been set-up for decline for awhile. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stock Wars: AstraZeneca Vs. Pfizer
Benzinga’s Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is ... 
Via Benzinga
AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials
AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, ... 
Via Benzinga
Exposures COVID-19
Why Lilly's Near-Term Prospects Aren't Looking That Great
The big drugmaker is relying heavily on one new product that likely won't be able to keep up its momentum. 
Via The Motley Fool
New Investor? Buy These 2 Rock-Solid Stalwarts for Safety and Dividends
These buy-and-forget investments can be pillars for your portfolio for not just years, but decades. 
Via The Motley Fool
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.